[PRESS RELEASE]

MBL co-sponsors a seminar on MEBRIGHT™ genitalium Plus DR Kit atthe 98th JAID / the 72nd JSC ConferenceTokyo, Japan - June 20th, 2024 - Medical and Biological Laboratories Co., Ltd. (CEO: Hiroki Ito, “MBL”),
a JSR Life Sciences Company, announces that it will co-sponsor a luncheon seminar on the "MEBRIGHT™
genitalium Plus DR Kit" (hereafter referred to as "this reagent") which received approval from theJapanese Ministry of Health, Labour and Welfare (MHLW) on December 18th, 2023, at the 98th Annual
Meeting of the Japanese Society for Infectious Diseases and the 72nd Annual Meeting of the JapaneseSociety for Chemotherapy held at the Kobe International Conference Center / Kobe International
Exhibition Hall 1 from June 27th (Thursday) to 29th (Saturday), 2024.
MEBRIGHT™ genitalium Plus DR Kit is a nucleic acid amplification test to detect Mycoplasma genitalium(MG) and major mutations in its 23S rRNA gene domain V region1) (A2071G, A2071C, A2071T, A2072G,A2072C, A2072T) in DNA extracted from urine and cervical abrasions. This reagent is expected tocontribute to reducing the burden on patients with sexually transmitted diseases (STDs) through theappropriate therapeutic medication by simultaneously detecting mutations associated with drug
resistance of MG.
The luncheon seminar scheduled for June 27th (Thu.) will be chaired by Dr. Takashi Deguchi of Central
Japan International Medical Center, and speakers will be Dr. Mitsuru Yasuda, Department of Infection
Control and Laboratory Medicine, Sapporo Medical University School of Medicine, and Dr. Shin Ito of Ai
Clinic, who will speak on the "importance of simultaneous detection of Mycoplasma genitalium and drug
resistance in STDs.”

About Sexually Transmitted Diseases and Mycoplasma genitalium:STDs, represented by urethritis in men and cervicitis in women, have become a global public health issue
with more than one million infections per day worldwide, resulting in a decreased quality of life and serious
medical conditions.
Urethritis is classified into gonococcal and nongonococcal urethritis, and although chlamydia was known
to be the primary causative microorganism of nongonococcal urethritis, recent studies have revealed that
MG accounts for approximately 10% of the causative microorganisms of urethritis.
In the diagnosis of MG infection, testing by nucleic acid amplification is required because it cannot becultured in general. In the treatment, MG is acquiring drug-resistant mutations against first-line
macrolide antimicrobials and second-line new quinolone antimicrobials, and there is an urgent need toprevent their spread.

References:
1. Sexually Transmitted Diseases Working Group, JAID/JSC Committee for the Preparation of Treatment Guides andGuidelines for Infectious Diseases, The Japanese Associations of Infectious Diseases and The Japanese Society ofChemotherapy. JAID/JSC Guidelines for the Treatment of Infectious Diseases
2. The Japan Society of Sexually Transmitted Diseases. Sexually Transmitted Diseases Diagnosis and Treatment
Guidelines 2020
3. Jensen, J. S. Methods Mol Biol. 2012, vol. 903, p. 129-139.

Product Information:
Product Name

:MEBRIGHT™ genitalium Plus DR Kit

Approval No.

:30500EZX00055000

Intended use:Detection of Mycoplasma genitalium DNA and macrolide resistance-related mutant
DNA in Mycoplasma genitalium 23S rRNA genes in urine or cervical abrasions(diagnostic aid for Mycoplasma genitalium infection and Mycoplasma genitalium
macrolide-resistant infection)

Testing method:Real time-PCR

Package Size:96 tests/kit

Shelf life:24 months

Contact:
Medical & Biological Laboratories Co., Ltd.
Technical Support
Head Quarter: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8
Minato-ku, Tokyo

105-0012

Shibadaimon,Japan

TEL: +81-3-6854-3613
E-mail: https://www.mblbio.com/e/inq/ivd.html
About Medical & Biological Laboratories Co., Ltd.:
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer inJapan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) andreagents for basic research. It has now expanded its business not only to the immunological field but also
to the field of genetic diagnosis.
In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases,etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top
manufacturer in Japan and contributing to medical care in this field where there are many intractablediseases. In the field of oncology, we are contributing to personalized medicine by developing companion
diagnostics that predict the effects of drugs.
https://www.mbl.co.jp/